linjc16/ctgov huggingface dataset:
Nebulized Corticosteroid for Post Extubation Stridor in Children

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy and adverse effect of nebulized corticosteroid to prevent post-extubation stridor in children.

Detailed Description
-----------------
The guideline for prevention and treatment of post-extubation stridor in children is inconclusive include Nebulized epinephrine and intravenous corticosteroid. Nebulized corticosteroid is alternative treatment for viral croup. the rationale of this study to evaluate the efficacy of nebulized fluticasone propionate to prevent pediatric post-extubation stridor

Official Title
-----------------
Nebulized Corticosteroid for Post Extubation Stridor in Children: A Randomized Double Blind Controlled Trial

Conditions
-----------------
Stridor

Intervention / Treatment
-----------------
* Drug: fluticasone propionate
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children age between 1 month old - 18 year old who was intubated Exclusion Criteria: Palliative care Anatomical abnormalities of airway; subglottic stenosis Neuromuscular disease with negative inspiratory force < - 30 mmHg Need positive pressure after extubation

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: fluticasone propionate<br>Fluticasone 1 mg + Normal saline (NSS) upto 4 ml nebulized after extubation | Drug: fluticasone propionate<br>* Flixotide 1 mg + NSS upto 4 ml nebulized after extubation. Record vital signs and modified Westley score at 0, 15, 30, 60 min and 2,4,6 hours<br>* Other names: Flixotide;|
| Placebo Comparator: placebo<br>Normal saline (NSS) 4 ml nebulized after extubation | Drug: Placebo<br>* NSS 4 ml nebulized after extubation. Record vital signs and modified Westley score at 0, 15, 30, 60 min and 2,4,6 hours<br>* Other names: normal saline;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| post-extubation stridor | patient who developed stridor after extubation within 6 hours | 6 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| treatment failure | patient who required escalating of respiratory support such as noninvasive positive pressure ventilation or reintubation within 24 hours | 24 hour | 
| adverse events | hyperglycemia, oral thrust or GI bleeding | 24 hour |
Weight Loss Prior Mamma Reduction - A Pilot Study

Study Overview
=================
Brief Summary
-----------------
Due to a higher risk of complications, obese and overweight patients with macromastia are in Denmark prohibited mammoplasty , as BMI must be within normal range, i.e. BMI < 25 kg/m2. The study is a pilot study with a diet intervention group and no control group. The intervention is a 12 week low energy diet pre-operative weight loss program investigating if this will result in weight loss making the overweight and obese patients eligible for breast reduction surgery i.e. BMI < 25.

Official Title
-----------------
Weight Loss by Low Energy Diet as Treatment Prior Mamma Reduction in Overweight Women - A Pilot Study

Conditions
-----------------
Weight Loss, Hypertrophy

Intervention / Treatment
-----------------
* Dietary Supplement: Low energy diet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: entitled to mammoplasty, motivated towards participation in a weight loss program BMI within the range 25.5 to 35 kg/m2 Exclusion Criteria: more than 65 years of age insulin-dependent diabetes chronic heart, liver or kidney failure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Low energy diet<br>Low energy diet (800 kcal/d) for eight weeks, following 4 weeks on reintroduction supplying 1200 kcal/d. | Dietary Supplement: Low energy diet<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Weight loss | Measurement of weight to nearest 0.1 kg on category III approved body weight | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Breast volumen | measure of breast volumen | 12 weeks | 
| Breast size | anthropometric measurements of the breasts by measuring tape. | 12 weeks | 
| Pain and discomfort | Questionnaire on pain in head, neck, shoulders | 12 weeks |
Development of Outcome-measures for Physically Active Patients With Hip and Groin Pain

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to develop an evaluative questionnaire, to evaluate patients with hip and groin disability, and a strength measurement for the hip, for patients with hip and groin disability. Both measurement instrument are aimed for evaluating the natural course and different treatment modalities in patients with hip and groin disability.

Official Title
-----------------
Development of Outcome-measures for Physically Active Patients With Hip and Groin Pain

Conditions
-----------------
Hip Disability, Groin Disability

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hip and/groin pain more than 6 weeks Physically active Exclusion Criteria: Systemic diseases Physically inactive

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pateints with longstanding hip and/groin pain<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient reported questionnaire |  | 1-2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Strength measurement for the hip |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Questionnaire, Hip, Groin, Disability, Strength, To develop two new outcome measures for patients with hip and groin disability
Clinical Study and Gene Mutation Analysis of Adrenoleukodystrophy in Taiwanese Children

Study Overview
=================
Brief Summary
-----------------
Study the clinical manifestations and gene mutation of Taiwanese ALD patients

Official Title
-----------------
Clinical Study and Gene Mutation Analysis of Adrenoleukodystrophy in Taiwanese Children

Conditions
-----------------
Adrenoleukodystrophy

Intervention / Treatment
-----------------
* Procedure: blood sampling and medical records


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: X-ALD patients and family Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: blood sampling and medical records|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Search as text words in Annotation & Scope Note
Postoperative Sleep Disturbances After Zolpidem Treatment in Fast-track Hip and Knee Replacement

Study Overview
=================
Brief Summary
-----------------
Sleep after surgery has been found to be very distrubed immediately after major surgery. This is also seen after fast-track hip and knee replacement with length of stay of less than 3 days. Disturbed sleep has many adverse effects i.e. fatigue, possible hyperalgesia and decline in cognitive abilities.

Official Title
-----------------
Postoperative Sleep Disturbances After Zolpidem Treatment in Fast-track Hip and Knee Replacement

Conditions
-----------------
Sleep Duration on the First Night After Surgery

Intervention / Treatment
-----------------
* Drug: Zolpidem
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Total hip or knee replacement in fast-track setup Age 60 years or above ASA class 1-3 Exclusion Criteria: Anesthesia within the pas 30 days Daily use of alcohol > 21 units / week Use of anxiolytics or hypnotics within the past 30 days Inability to read and understand Danish Marked reduction of sight or hearing Parkinson's disease or other neurological disaese causing function deficits Inability to cooperate to sleep monitoring allergy to the drug tested

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Zolpidem<br> | Drug: Zolpidem<br>* The effect of Zolpidem 10 mg for the first night after surgery is asssessed using PSG<br>|
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* Pacebo tablet, blinded given on the first night after surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in sleep time on the first postoperative night compared to preoperatively. | The primary endpoint is an evaluation of sleep stages on the first night postoperatively compared to preoperative measures for the same individual | first night postoperatively - 24 hours |
Neuroeconomic Approach of Food Nutritionnal Assesment

Study Overview
=================
Brief Summary
-----------------
This fMRI study evaluated the cognitive mechanisms and the cerebral substrate of decision making when evaluating the healthiness of food products with nutritional information displayed either with a Traffic Light system, a colored nutritional label, and a Guideline Daily Amount system, a numeric label.

Detailed Description
-----------------
The investigators postulated that Traffic Light label would recruit emotion processes and activation of subjacent cerebral networks. On the contrary, the nutritional information presented in a Guideline Daily Amount label, would recruit, due to its numeric format and higher complexity, supplementary cognitive processes and activation of related brain regions.

Official Title
-----------------
Neural Networks of Decision Making Processes Triggered by Food Labels

Conditions
-----------------
Healthy Volunteer

Intervention / Treatment
-----------------
* Other: Magnetic Resonance Imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: signed informed consent medical exam completed before participation in reserach to be insured under the social security system to be an adult between 18 and 50 years Exclusion Criteria: counter-argument to magnetic field exposure neurological or psychiatric disorder including eating disorders had

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Healthy Volunteer<br> | Other: Magnetic Resonance Imaging<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of cerebral areas's activation | MRI | About two hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Food, Emotion, Health, Nutrition, Heuristic, Reasoning, Magnetic Resonance Imaging
Phytoestrogens and Memory Decline in Menopause

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate whether soy-derived phytoestrogens taken as dietary supplements improve memory function in postmenopausal women who have experienced early memory decline.

Detailed Description
-----------------
Accumulating data has indicated that estrogens mediate enhancing effects on cognition and mood and may play a prophylactic role against age- and disease-related cognitive-cerebral decline. Phytoestrogens are plant-derived substances that have demonstrated estrogenic activity, but there is little prospective research regarding their effects on mental function. Mental health practitioners generally do not prescribe phytoestrogens. However, many women experiencing peri- and post-menopausal symptoms use marketed phytoestrogens under the perception of general health benefits, including presumably enhanced mental function. The purpose of this study is to develop preliminary data regarding the efficacy of isoflavone phytoestrogens in improving cognitive function in late middle-aged and elderly postmenopausal women with symptoms of memory impairment. Participants in this study will be randomized to receive either isoflavone supplementation or placebo. The study will last for 16 weeks, during which participants will take the supplement pill or placebo three times a day. Participants will be assessed at study entry and at Week 16 for changes in basal cortisol levels, mood, and neuropsychological measures of executive function ability and episodic memory.

Official Title
-----------------
Phytoestrogens and Cognition in Menopause

Conditions
-----------------
Memory Loss, Postmenopause

Intervention / Treatment
-----------------
* Drug: Isoflavones


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Postmenopausal women Mild memory or cognitive decline that does not meet the criteria for probable dementia Exlcusion Criteria Hormone replacement therapy within 2 months prior to study entry Psychiatric medications within 30 days prior to study entry

Ages Eligible for Study
-----------------
Minimum Age: 62 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Isoflavones|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Postmenopausal, Memory Loss, Cognition, Phytoestrogens
Risk Factors for Residual Neoplasia After Endoscopic Mucosal Resection

Study Overview
=================
Brief Summary
-----------------
Laterally Spreading Tumors (LST) are important precursosrs of invasive colorectal cancer. Endoscopic treatment has replaced surgery in most of the cases. Nevertheless, after conventional Endoscopic Mucosal Resection (CER), Local Residual Neoplasia (LRN) is an issue. Therefore, endoscopic follow-up and treatment are necessary. To decrease its occurrence, the risk factors of LRN shoudl be identified. Thereafter, in high-risk patients, other modalities of initial treatment including Endoscopic Submucosal Dissection (ESD) and surgical treatment, could be considered. The purpose of this prospective study is to identify risk factors associated with the presence of LRN after CER of LSTs.

Official Title
-----------------
Risk Factors for Local Residual Neoplasia After Convetional Endoscopic Mucosal Resection of Laterally Spreading Tumors

Conditions
-----------------
Colorectal Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all consecutive patients referred for EMR of LST Exclusion Criteria: polyposis syndromes previous therapeutic attempt

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurence of Local Residual Neoplasia (LRN) | LRN was defined as a histologically confirmed neoplastic tissue in the biopsy samples obtained from post-resection scar during follow-up colonoscopy 3 months after endoscopic resection | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of Selected Risk Factors for Local Residual Neoplasia (LRN) | Evaluation of selected patient- and lesion-related risk factors associated with LRN (gender, age, lesion size, location, morphology, pit pattern, histology, type of resection, and others) | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endoscopic Mucosal Resection, Laterally Spreading Tumor, Local Residual Neoplasia, Colonoscopy, Therapy
Impact of a Triage Liaison Physician

Study Overview
=================
Brief Summary
-----------------
Due to an increasing number of patients admitted in emergency departments, many patients cannot be evaluated immediately after their admission. The function of triage liaison physician was introduced in Spring 2015. The objective of this study is to evaluate the impact of this new function on patients' flow in the ED.

Detailed Description
-----------------
Geneva University Hospitals (GUH) emergency department (ED) admits more than 64000 patients every year. These patients are triaged using the Swiss Emergency Triage Scale (SETS), a 4-level triage scale. The SETS imposes time objectives until the first medical evaluation (20 minutes for SETS 2, 2 hours for SETS 3). In 2014, only 60% of level-2 and 63% of level-3 emergencies were evaluated within 20 and 120 minutes respectively. A triage liaison physician was introduced in Spring 2015 with the mission to help triage nurse in their decisions and to evaluate quickly the patients that cannot be immediately installed in an ED evaluation room. The objective of this study is to evaluate the impact of the triage liaison physician on the times to first medical evaluation.

Official Title
-----------------
Impact of a Triage Liaison Physician on the Time to First Medical Evaluation in the Emergency Departement

Conditions
-----------------
Emergencies, Triage

Intervention / Treatment
-----------------
* Other: Triage liaison physician


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >= 16 y admitted in GUH ED Exclusion Criteria: patients triaged to outpatient clinics

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Before triage liaison physician<br>All patients admitted before the introduction of the function of triage liaison physician. | |
| After triage liaison physician<br>All patients admitted after the introduction of the function of triage liaison physician. | Other: Triage liaison physician<br>* A triage liaison physician is present from 7:30 am to 10:30 pm, Monday to Friday, with the mission to evaluate quickly patients who cannot be immediately installed in an ED room<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients evaluated within SETS objectives | Proportion of patients evaluated within time objective as defined by SETS standards. | Within 120 minutes after ED triage | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to first medical contact | Time elapsed between triage and first medical evaluation | Within 24 hours after ED triage |